Journal articleJ Med Cases2022
Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.
- Journal
- J Med Cases
- Published
- 7 May 2022
- Citations
- 17
- Type
- Article
- License
- cc by-nc
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract cc by-nc
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with 5-year survival rate of 10%. Evidence about pembrolizumab usage for PDAC is limited even though it is Food and Drug Administration (FDA)-approved for treatment of advanced pancreatic cancer with deficient mismatch repair expression (dMMR) or high tumor mutational burden (TMB) where as there is limited evidence for programmed death-ligand 1 (PD-L1)-positive PDACs. … Excerpt only: this text is the publisher’s. Read it in full at the source.